Annual CFO
-$357.99 M
-$113.28 M-46.29%
31 December 2023
Summary:
Denali Therapeutics annual cash flow from operations is currently -$357.99 million, with the most recent change of -$113.28 million (-46.29%) on 31 December 2023. During the last 3 years, it has fallen by -$146.60 million (-69.35%). DNLI annual CFO is now -186.02% below its all-time high of $416.15 million, reached on 31 December 2020.DNLI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$59.14 M
+$32.08 M+35.17%
30 September 2024
Summary:
Denali Therapeutics quarterly cash flow from operations is currently -$59.14 million, with the most recent change of +$32.08 million (+35.17%) on 30 September 2024. Over the past year, it has increased by +$39.52 million (+40.06%). DNLI quarterly CFO is now -111.51% below its all-time high of $513.91 million, reached on 31 December 2020.DNLI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$362.64 M
+$28.22 M+7.22%
30 September 2024
Summary:
Denali Therapeutics TTM cash flow from operations is currently -$362.64 million, with the most recent change of +$28.22 million (+7.22%) on 30 September 2024. Over the past year, it has dropped by -$4.64 million (-1.30%). DNLI TTM CFO is now -186.26% below its all-time high of $420.40 million, reached on 31 March 2021.DNLI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
DNLI Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +40.1% | -1.3% |
| 3 y3 years | -69.3% | +9.7% | -71.5% |
| 5 y5 years | -136.2% | -24.1% | -139.2% |
DNLI Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -69.3% | at low | -37.9% | +48.0% | -71.5% | +12.2% |
| 5 y | 5 years | -186.0% | at low | -111.5% | +48.0% | -186.3% | +12.2% |
| alltime | all time | -186.0% | at low | -111.5% | +48.0% | -186.3% | +12.2% |
Denali Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$59.14 M(-35.2%) | -$362.64 M(-7.2%) |
| June 2024 | - | -$91.22 M(-19.7%) | -$390.86 M(-5.3%) |
| Mar 2024 | - | -$113.62 M(+15.2%) | -$412.81 M(+15.3%) |
| Dec 2023 | -$357.99 M(+46.3%) | -$98.66 M(+12.9%) | -$357.99 M(+7.8%) |
| Sept 2023 | - | -$87.36 M(-22.8%) | -$332.00 M(+10.0%) |
| June 2023 | - | -$113.17 M(+92.5%) | -$301.68 M(+30.4%) |
| Mar 2023 | - | -$58.80 M(-19.1%) | -$231.41 M(-5.4%) |
| Dec 2022 | -$244.72 M(+15.8%) | -$72.66 M(+27.4%) | -$244.72 M(+3.0%) |
| Sept 2022 | - | -$57.05 M(+33.0%) | -$237.55 M(+7.0%) |
| June 2022 | - | -$42.90 M(-40.5%) | -$221.94 M(-4.9%) |
| Mar 2022 | - | -$72.11 M(+10.1%) | -$233.26 M(+10.3%) |
| Dec 2021 | -$211.39 M(-150.8%) | -$65.49 M(+58.1%) | -$211.39 M(-157.4%) |
| Sept 2021 | - | -$41.43 M(-23.6%) | $368.02 M(-10.1%) |
| June 2021 | - | -$54.22 M(+7.9%) | $409.54 M(-2.6%) |
| Mar 2021 | - | -$50.24 M(-109.8%) | $420.40 M(+1.0%) |
| Dec 2020 | $416.15 M | $513.91 M(>+9900.0%) | $416.15 M(-386.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $86.00 K(-100.2%) | -$145.41 M(-17.3%) |
| June 2020 | - | -$43.36 M(-20.4%) | -$175.93 M(+0.1%) |
| Mar 2020 | - | -$54.49 M(+14.4%) | -$175.75 M(+15.9%) |
| Dec 2019 | -$151.58 M(-402.5%) | -$47.64 M(+56.5%) | -$151.58 M(+1310.3%) |
| Sept 2019 | - | -$30.43 M(-29.5%) | -$10.75 M(-29.0%) |
| June 2019 | - | -$43.17 M(+42.4%) | -$15.13 M(+9.8%) |
| Mar 2019 | - | -$30.32 M(-132.5%) | -$13.78 M(-127.5%) |
| Dec 2018 | $50.12 M(-165.4%) | $93.19 M(-367.6%) | $50.12 M(-181.6%) |
| Sept 2018 | - | -$34.82 M(-16.7%) | -$61.41 M(+26.6%) |
| June 2018 | - | -$41.82 M(-224.6%) | -$48.50 M(+100.0%) |
| Mar 2018 | - | $33.58 M(-283.1%) | -$24.25 M(-68.4%) |
| Dec 2017 | -$76.64 M(+6.6%) | -$18.34 M(-16.4%) | -$76.64 M(+31.5%) |
| Sept 2017 | - | -$21.92 M(+24.8%) | -$58.30 M(+60.3%) |
| June 2017 | - | -$17.57 M(-6.6%) | -$36.38 M(+93.4%) |
| Mar 2017 | - | -$18.81 M | -$18.81 M |
| Dec 2016 | -$71.91 M(+377.7%) | - | - |
| Dec 2015 | -$15.05 M | - | - |
FAQ
- What is Denali Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Denali Therapeutics?
- What is Denali Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Denali Therapeutics?
- What is Denali Therapeutics quarterly CFO year-on-year change?
- What is Denali Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Denali Therapeutics?
- What is Denali Therapeutics TTM CFO year-on-year change?
What is Denali Therapeutics annual cash flow from operations?
The current annual CFO of DNLI is -$357.99 M
What is the all time high annual CFO for Denali Therapeutics?
Denali Therapeutics all-time high annual cash flow from operations is $416.15 M
What is Denali Therapeutics quarterly cash flow from operations?
The current quarterly CFO of DNLI is -$59.14 M
What is the all time high quarterly CFO for Denali Therapeutics?
Denali Therapeutics all-time high quarterly cash flow from operations is $513.91 M
What is Denali Therapeutics quarterly CFO year-on-year change?
Over the past year, DNLI quarterly cash flow from operations has changed by +$39.52 M (+40.06%)
What is Denali Therapeutics TTM cash flow from operations?
The current TTM CFO of DNLI is -$362.64 M
What is the all time high TTM CFO for Denali Therapeutics?
Denali Therapeutics all-time high TTM cash flow from operations is $420.40 M
What is Denali Therapeutics TTM CFO year-on-year change?
Over the past year, DNLI TTM cash flow from operations has changed by -$4.64 M (-1.30%)